The German biotech company, 4SC AG, has reported preliminary Phase 2a data for its small molecule drug for inflammatory bowel disease that showed a total response rate of 88.5% in patients who had been dependent on corticosteroids. ---Subscribe to MedNous to access this article--- Company News
